Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price reduced by Barclays from $55.00 to $26.00 in a report published on Friday,Benzinga reports. Barclays currently has an overweight ...

Intellia Therapeutics Inc. is shaking up its Cambridge and Waltham real estate footprints. The gene-editing company h as ...

If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. Revenues were better than expected, with US$58m in revenue ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and ...

Intellia Therapeutics (NASDAQ:NTLA) traded higher on Thursday as investors cheered pipeline updates the gene-editing biotech ...

Intellia Therapeutics Inc (($NTLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Intellia Therapeutics’ Earnings ...

Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was ...